The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is one of the

10 Stocks That Have the Potential to Rise 1000%.

On May 21, 2026, BTIG raised the firm’s price target on Rapport Therapeutics, Inc. (NASDAQ:RAPP) to $65 from $53 and maintained a Buy rating on the shares. BTIG cited clinical execution behind its more constructive stance on RAP-219 in bipolar mania, with Phase 2 topline results pulled forward to Q4 from the first half of FY27 due to steady, uniform enrollment.

On May 18, 2026, Truist assumed coverage of Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a Buy rating and a price target of $56, up from $44. Truist said its thesis remains largely consistent with its prior view, seeing RAP-219 as an attractive, differentiated epilepsy asset. The firm cited early efficacy data suggesting best-in-category potential in focal onset seizures, along with upside optionality in bipolar mania that is not reflected in current projections.

Earlier in May, Rapport Therapeutics, Inc. (NASDAQ:RAPP) reported Q1 EPS of (42c), compared to the consensus estimate of (71c). Revenue totaled $20,000, below the consensus estimate of $6M. CEO Abraham N. Ceesay said Rapport entered 2026 with “strong momentum” across the RAP-219 development program, supported by Phase 2a follow-up data in focal onset seizures and progress toward Phase 3 trials. Ceesay also cited upcoming milestones in epilepsy, bipolar mania, and the company’s long-acting injectable formulation.

Africa Studio/Shutterstock.com

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for central nervous system disorders.

While we acknowledge the potential of RAPP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.